| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b835f4e34592b9e7c3f2abb90ec6c65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b1c3d42031bad5ab0ae64b261d8e4d1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b6e07d0ba65166efb372e1f007f8d92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00dd1941b378beb2c7b5f25ae39f073c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36087061fd8ea177c7b2002b0cd7310c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8266959f91562150a83544e07a09733d |
| publicationDate |
2018-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3344658-A1 |
| titleOfInvention |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
| abstract |
The present disclosure relates to isolated monoclonal antibodies which bind to the human T-cell immunoglobulin and ITIM domain (TIGIT). The antibodies are characterized by their CDRs sequences. Humanized and bispecific anti TIGIT antibodies are also disclosed. The selected and claimed antibodies show a superior killing activity of effector cells, exhibit high affinity to TIGIT thus prevent the inhibitory effect of the TIGIT receptor and are therefore suitable for use as anti-cancer agents. |
| priorityDate |
2015-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |